Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma

Seidel Clemens; Kortmann Rolf-Dieter

首页> 外文期刊>Strahlentherapie und Onkologie >Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma

【24h】

Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma

机译：Lomustine和Temozolomide与放疗新的一线治疗选择，用于MGMT启动子甲基化胶质母细胞瘤的患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Strahlentherapie und Onkologie》 |2019年第9期|共2页
作者
Seidel Clemens; Kortmann Rolf-Dieter;
展开▼
作者单位

Univ Klin Radioonkol &

Strahlentherapie Stephanstr 9a D-04103 Leipzig Germany;

Univ Klin Radioonkol &

Strahlentherapie Stephanstr 9a D-04103 Leipzig Germany;

展开▼
收录信息
原文格式 PDF
正文语种 ger
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma [J] . Seidel Clemens, Kortmann Rolf-Dieter Strahlentherapie und Onkologie . 2019,第9期

机译：Lomustine和Temozolomide与放疗新的一线治疗选择，用于MGMT启动子甲基化胶质母细胞瘤的患者
2. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial [J] . Herrlinger Ulrich, Tzaridis Theophilos, Mack Frederic, The Lancet . 2019,第10172期

机译：Lomustine-Temozolomide联合治疗与新诊断的MGMT启动子新诊断的胶质母细胞瘤患者的标准替莫唑胺治疗（Ceteg / NoA-09）：随机，开放标签，第3阶段试验
3. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial [J] . Weller Johannes, Tzaridis Theophilos, Mack Frederic, The lancet oncology . 2019,第10期

机译：与新诊断的MgMT-甲基化胶质细胞瘤（Ceteg / NoA-09）的患者患者与Lomustine-temozolomide与替莫斯汀 - 替莫替莫唑胺类患者有关的生活质量和神经过度认知功能
4. Multiregional Radiomics Phenotypes at MR Imaging Predict MGMT Promoter Methylation in Glioblastoma [C] . Zhi-Cheng Li, Yinsheng Chen, Qiuchang Sun World Congress on Medical Physics and Biomedical Engineering . 2019

机译：MR成像在胶质母细胞瘤中预测MGMT启动子甲基化的多径辐射瘤表
5. Overcoming Temozolomide Resistance in Glioblastoma Multiforme with MGMT-Targeting Spherical Nucleic Acids. [D] . Sita, Timothy L. 2017

机译：MGMG靶向球形核酸克服胶质母细胞瘤中替莫唑胺的耐药性。
6. Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised open-label phase 3 trial [O] . Sunit Das, Arjun Sahgal, James R. Perry 2020

机译：评论：洛莫司汀-替莫唑胺联合治疗与标准替莫唑胺治疗新诊断患有甲基化MGMT启动子的胶质母细胞瘤患者（CeTeG / NOA-09）：一项随机开放标签的3期试验
7. ACTR-47. COMBINED TREATMENT WITH HYPOFRACTIONATED RADIOTHERAPY AND TEMOZOLOMIDE BENEFITS OVER SINGLE TREATMENT IN ELDERLY PATIENTS WITH METHYLATED BUT NOT UNMETHYLATED MGMT GLIOBLASTOMA [O] . Motoo Nagane, Yuki Yamagishi, Keiichi Kobayashi, 2017

机译：ACTR-47。在老年甲基化但不是未甲基化的MGMT胶质母细胞瘤中对老年患者的单治疗效应和替替替莫替莫酯的结合治疗

Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma

著录项

相似文献

相关主题

期刊订阅